164 Spam-Free Article(s) Found
Sort:
Like
Filter:
All
Symbol Name Last Close Mkt Cap DailyStocks'
Rating
Our DailyStocks’ Rating System is a proprietary algorithm that combines the vote of the investor community and legendary trader Richard Dennis’ Turtle Trader System and the System Rules of the Turtle Traders Each day, we generate Buy, Sell, Uptrend or Downtrend signals for 3000 Stocks in the U.S. Markets.
Vote Now!
Monday’s Close
NVO Novo Nordisk A/S $47.64 $114.84B N/A
Article Searches
Novo Nordisk: Positive CHMP Nod for Tresiba Label Expansion http://www.zacks.com/stock/news/254428/novo-nordisk-positive-chmp-nod-for-tresiba-label-expansion?cid=CS-ZC-FT-254428 Mar 28, 2017 - Novo Nordisk A/S (NVO) announced that the Committee for Medicinal Products for Human Use (CHMP), has issued a positive opinion suggesting an update to the label for Tresiba (insulin degludec) to include data from the SWITCH studies.
Merck's Bid to Add Cardiovascular Data on Januvia Label Fails http://www.zacks.com/stock/news/255888/mercks-bid-to-add-cardiovascular-data-on-januvia-label-fails?cid=CS-ZC-FT-255888 Apr 10, 2017 - Merck announced that the FDA has denied approval to include cardiovascular outcomes data on the labels of its diabetes drug, Januvia (sitagliptin) and other medicines containing Januvia.
5 Reasons Why VIVUS (VVUS) Stock Should Be in Your Portfolio http://www.zacks.com/stock/news/261774/5-reasons-why-vivus-vvus-stock-should-be-in-your-portfolio?cid=CS-ZC-FT-261774 May 24, 2017 - Campbell, CA -based VIVUS, Inc. (VVUS) is a biopharmaceutical company developing and commercializing innovative, next-generation therapies to address unmet medical needs
AstraZeneca's Bydureon Fails to Reduce Cardiovascular Risk http://www.zacks.com/stock/news/261771/astrazenecas-bydureon-fails-to-reduce-cardiovascular-risk?cid=CS-ZC-FT-261771 May 24, 2017 - AstraZeneca plc (AZN) announced top-line results from the EXSCEL study evaluating the cardiovascular (CV) safety profile of its type II diabetes drug Bydureon.
Novo Nordisk (NVO) Presents Data for Type II Diabetes Drug http://feeds.benzinga.com/~r/benzinga/~3/h1-2h-7NIMw/novo-nordisk-nvo-presents-data-for-type-ii-diabetes-drug Jun 14, 2017 -

Novo Nordisk A/S NVO announced positive results from the post-hoc analysis of the cardiovascular (CV) outcomes study, LEADER on Victoza.

read more

Why Novo Nordisk A/S (ADR) Jumped 10.6% In May https://www.fool.com/investing/2017/06/10/why-novo-nordisk-as-adr-jumped-106-in-april.aspx?source=iedfolrf0000001 Jun 10, 2017 - Traders cheered the company's first quarter earnings report.
Novo Nordisk A/S Continues Its Comeback https://www.fool.com/investing/2017/08/14/novo-nordisk-as-continues-its-comeback.aspx?source=iedfolrf0000001 Aug 14, 2017 - A solid-enough second quarter from the diabetes specialist boosts investors' confidence in a turnaround.
3 High-Yield Pharmaceutical Stocks https://www.fool.com/investing/2017/08/22/3-high-yield-pharmaceutical-stocks.aspx?source=iedfolrf0000001 Aug 22, 2017 - Pfizer, GlaxoSmithKline, and Novo Nordisk all offer up temptingly high yields. Here's why they're worth putting on your radar.
Novo Nordisk's (NVO) CEO Lars Fruergaard Jorgensen on Q2 2017 Results - Earnings Call Transcript https://seekingalpha.com/article/4097095-novo-nordisks-nvo-ceo-lars-fruergaard-jorgensen-q2-2017-results-earnings-call-transcript?source=feed_all_articles Aug 09, 2017 - Novo Nordisk A/S (NYSE:NVO) Q2 2017 Earnings Conference Call August 9, 2017 7:00 AM ET Executives Lars Fruergaard Jorgensen – President and Chief Executive Officer Mads Krogsgaard Thomsen – Executive
Novo Nordisk A/S Slogs Through the Year https://www.fool.com/investing/2017/11/07/novo-nordisk-as-slogs-through-the-year.aspx?source=iedfolrf0000001 Nov 07, 2017 - It was another lackluster quarter from the diabetes specialist.

Pages: 1234567891011...17

<<<Page 6>